Personalized Cancer Medicine

Personalized Cancer Medicine Market Outlook

The global personalized cancer medicine market is projected to reach approximately USD 180 billion by 2035, growing at a remarkable CAGR of around 12.5% during the forecast period from 2025 to 2035. The increasing prevalence of cancer worldwide, coupled with the ongoing advancements in genomics and biotechnology, is driving the growth of this market. Furthermore, personalized cancer therapies are becoming more appealing due to their potential to improve treatment outcomes by tailoring medical interventions to individual characteristics. The growing emphasis on precision medicine and the integration of artificial intelligence in drug discovery and development processes are also influential factors contributing to the market's expansion. With a focus on patient-centric healthcare, stakeholders in the healthcare ecosystem are increasingly investing in research and development activities aimed at delivering innovative and effective treatment modalities.

Growth Factor of the Market

Several growth factors are contributing to the surge in the personalized cancer medicine market. Firstly, the rise in the global incidence of cancer is a significant driver, as personalized treatments are effective in addressing the unique genetic profiles of tumors. Secondly, advancements in biotechnology, including the development of novel biomarker tests and genomic sequencing technologies, allow for more specific and effective treatment options. Thirdly, the growing acceptance and utilization of targeted therapies and immunotherapies among clinicians and patients are enhancing the market's appeal. Moreover, strategic collaborations among pharmaceutical companies, research institutions, and healthcare providers aim to accelerate innovation in personalized cancer treatments. Lastly, increased funding for cancer research from governments and private entities is fostering an environment conducive to the continued growth of this market.

Key Highlights of the Market

• The global personalized cancer medicine market is experiencing significant growth driven by advances in genomics and biotechnology.
• Targeted therapy remains the leading therapy type, garnering the largest market share due to its effectiveness in treating specific cancer types.
• North America holds the largest market share, primarily due to the presence of advanced healthcare infrastructure and ongoing research initiatives.
• Immunotherapy is witnessing rapid growth and is expected to be a key driver for market growth in the coming years.
• Collaboration between pharmaceutical companies and research institutions is facilitating the development of innovative treatment options tailored to individual patients.

By Therapy Type

Targeted Therapy:

Targeted therapy is one of the most significant segments in the personalized cancer medicine market, utilizing drugs that specifically target cancer cell mechanisms while sparing healthy cells. These therapies focus on specific molecular targets that are associated with cancer, such as mutations in genes or proteins that promote tumor growth. The personalized nature of targeted therapies enables oncologists to tailor treatment regimens based on an individual patient's tumor profile, which often leads to improved efficacy and reduced side effects. As our understanding of cancer biology deepens and new molecular targets are identified, the development of targeted therapies is on the rise, making this segment highly lucrative and a focal point for ongoing research.

Immunotherapy:

Immunotherapy has emerged as a revolutionary approach within personalized cancer treatment, leveraging the body's immune system to recognize and combat cancer cells. This type of therapy is particularly effective against various forms of cancer, including melanoma and non-small cell lung cancer. The personalized nature of immunotherapy allows for the creation of customized vaccines and T-cell therapies based on the unique characteristics of a patient's tumor. This segment is anticipated to experience substantial growth as clinical trials continue to demonstrate the efficacy of these treatments. Furthermore, the increasing approval of immunotherapeutic agents by regulatory bodies is fostering a conducive environment for market expansion.

Hormone Therapy:

Hormone therapy plays a crucial role in the treatment of hormone-sensitive cancers, such as breast and prostate cancers. This approach involves the use of medications that interfere with hormone production or action, effectively slowing or stopping the growth of cancer cells. The personalized aspect of hormone therapy lies in the ability to tailor treatment based on hormonal receptor status and other relevant biomarkers. With advancements in the understanding of cancer biology, this segment is evolving, and ongoing research is focused on identifying new targets for hormone therapy. The growing prevalence of hormone-sensitive cancers is also expected to contribute to the expansion of this therapy type.

Chemotherapy:

Chemotherapy remains a foundational component of cancer treatment, despite the rise of targeted therapies and immunotherapies. This treatment approach utilizes cytotoxic agents to kill rapidly dividing cancer cells, and while it is not as personalized as other modalities, advancements are being made to tailor chemotherapy regimens to specific cancer types and patient responses. Personalized chemotherapy protocols aim to minimize toxic side effects while maximizing treatment efficacy, ultimately leading to better patient outcomes. The market for chemotherapy is evolving as new agents are developed and existing ones are combined with targeted therapies and immunotherapies, enhancing overall effectiveness.

Radiation Therapy:

Radiation therapy utilizes high doses of radiation to kill cancer cells and shrink tumors, and its role in personalized cancer medicine is becoming increasingly prominent. Advances in technology, such as image-guided radiation therapy and stereotactic body radiation therapy, allow for more accurate targeting of tumors while minimizing exposure to surrounding healthy tissue. Personalized approaches in radiation therapy involve tailoring treatment plans based on the specific characteristics of the tumor, including its size, location, and genetic profile. As the precision of radiation delivery improves, this segment is expected to witness growth in conjunction with other personalized treatment modalities.

By Cancer Type

Breast Cancer:

Breast cancer is one of the most prevalent cancer types globally, and it has benefited significantly from advancements in personalized medicine. The integration of genomic profiling allows healthcare professionals to determine the most effective treatments tailored to an individual's cancer biology. Targeted therapies, such as HER2 inhibitors, have significantly improved outcomes for patients with HER2-positive breast cancer. Additionally, hormonal therapies are used for hormone receptor-positive breast cancer, contributing to the growing demand for personalized treatment options in this segment. With continued research and clinical trials, the market for personalized breast cancer treatments is expected to expand significantly.

Lung Cancer:

Lung cancer is another critical area where personalized cancer medicine is making substantial inroads. The identification of specific mutations, such as EGFR and ALK, has led to the development of targeted therapies that significantly improve patient survival rates. Personalized medicine in lung cancer allows oncologists to choose treatments based on the patient's unique genetic makeup and tumor characteristics. With the increasing incidence of lung cancer globally and the growing emphasis on precision medicine, this segment is projected to witness robust growth in the coming years, with ongoing research focused on discovering new targets and treatment options.

Prostate Cancer:

Prostate cancer is a significant health concern among men, and personalized medicine is revolutionizing its treatment landscape. The use of genomic tests, such as the Oncotype DX and Prolaris tests, helps in assessing the aggressiveness of the disease and guiding treatment decisions. Hormone therapy remains a cornerstone of treatment for advanced prostate cancer, particularly for patients with hormone-sensitive disease. Ongoing research into novel therapies and biomarkers is expected to enhance the personalization of prostate cancer treatment. The increasing awareness of personalized medicine's benefits is likely to drive the growth of this segment in the market.

Colorectal Cancer:

Colorectal cancer is one of the leading causes of cancer-related deaths, and personalized medicine is playing a pivotal role in improving treatment outcomes. Biomarker testing for mutations such as KRAS and BRAF has become essential in determining the best treatment approach, including the use of targeted therapies and immunotherapies. The growth of this segment is further supported by the increasing utilization of personalized treatment plans that consider individual patient profiles. As the understanding of colorectal cancer genomics advances, the availability of personalized therapies is expected to expand, contributing to the overall growth of the market.

Leukemia:

Leukemia, a type of blood cancer, has seen significant advancements in personalized medicine, particularly in the development of targeted therapies for specific genetic mutations. The use of genetic testing plays a crucial role in identifying patients who may benefit from targeted treatments, such as tyrosine kinase inhibitors or monoclonal antibodies. Personalized treatment approaches aim to improve patient outcomes by matching therapies to the genetic characteristics of leukemia. The growing awareness and research in this area are anticipated to drive the market for personalized leukemia treatments in the coming years, making it a key segment in the overall personalized cancer medicine landscape.

By End User

Hospitals:

Hospitals are one of the primary end users in the personalized cancer medicine market, providing a wide array of advanced treatment options and technologies for cancer patients. The integration of personalized treatment protocols in hospital settings is gaining traction, as oncologists increasingly utilize genomic and biomarker testing to guide treatment decisions. Furthermore, hospitals are investing in state-of-the-art diagnostic tools and therapies, enhancing their ability to provide tailored treatment plans. With the growing focus on patient-centered care and the adoption of precision medicine, hospitals are expected to continue leading the market in personalized cancer treatment.

Specialty Clinics:

Specialty clinics, dedicated to cancer care, have become vital players in the personalized cancer medicine landscape. These clinics often employ multidisciplinary teams, including oncologists, genetic counselors, and researchers, to deliver comprehensive care tailored to individual patient needs. With access to advanced diagnostic tools and targeted therapies, specialty clinics are well-positioned to implement personalized treatment strategies effectively. The growing trend towards outpatient care and the rise in personalized treatment options are likely to boost the market presence of specialty clinics in the coming years.

Cancer Research Institutes:

Cancer research institutes play a crucial role in advancing personalized cancer medicine through innovative research and clinical trials. These institutes are at the forefront of discovering new biomarkers and developing targeted therapies, contributing to the growing body of knowledge in the field. By collaborating with pharmaceutical companies and healthcare providers, cancer research institutes help translate scientific discoveries into clinical applications, paving the way for personalized treatment options. As new findings emerge and personalized therapies are validated, the influence of cancer research institutes in the market is expected to expand significantly.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are increasingly adopting personalized cancer treatment protocols, particularly in the context of outpatient procedures. These centers provide a convenient and efficient option for patients undergoing various cancer treatments, including minor surgical interventions and follow-up care. The personalized approach in ASCs involves the use of targeted therapies and tailored treatment plans, enhancing patient outcomes while minimizing hospital stays. As the demand for outpatient services rises, particularly in the wake of ongoing healthcare reforms, ASCs are expected to play an expanding role in the personalized cancer medicine market.

By Testing Type

Genomic Testing:

Genomic testing is a cornerstone of personalized cancer medicine, enabling the identification of specific mutations and genetic alterations associated with various cancers. This testing allows healthcare professionals to tailor treatment strategies based on the genetic profile of a patient's tumor, leading to more effective and targeted therapies. The increasing availability of next-generation sequencing technologies has propelled the adoption of genomic testing in clinical settings. As patients demand more personalized treatment options and as research continues to unveil new biomarkers, the genomic testing segment is expected to experience substantial growth in the coming years.

Biomarker Testing:

Biomarker testing involves the analysis of biological molecules in a patient's tumor or blood to provide insights into the disease's characteristics. This testing is vital for determining the best therapeutic approach for patients, particularly in identifying candidates for targeted therapies and immunotherapies. The growing emphasis on precision medicine has led to an increase in the utilization of biomarker tests, as they play a critical role in guiding treatment decisions. As researchers discover more biomarkers linked to specific cancer types, the market for biomarker testing is anticipated to expand significantly, enhancing its contribution to personalized cancer medicine.

Imaging:

Imaging technologies are essential for the diagnosis and monitoring of cancer, and their role is becoming increasingly personalized. Advanced imaging modalities, such as PET scans and MRI, are being integrated with molecular profiling to provide a comprehensive view of a patient's cancer. Personalized imaging approaches facilitate the identification of tumor characteristics and treatment responses, enabling oncologists to make informed decisions tailored to individual patients. As imaging technology continues to evolve, the demand for personalized imaging solutions in cancer care is expected to grow, contributing to the overall market expansion.

Blood Tests:

Blood tests are gaining traction in personalized cancer medicine, particularly in the realm of liquid biopsies. These tests analyze circulating tumor DNA and other biomarkers in the bloodstream, providing non-invasive insights into tumor dynamics and treatment responses. The ability to monitor cancer progression and treatment efficacy through blood tests enhances the personalization of care by allowing for timely adjustments to treatment plans. With increasing advancements in technology and a growing emphasis on non-invasive diagnostic methods, the blood testing segment is poised for significant growth in the personalized cancer medicine market.

Biopsy:

Biopsy remains a critical component of cancer diagnosis and personalized treatment planning. This procedure involves obtaining tissue samples from tumors for analysis, allowing oncologists to understand the tumor's genetic makeup and behavior. The development of advanced biopsy techniques, such as liquid biopsies and minimally invasive procedures, has made it possible to obtain crucial information about tumors without the need for extensive surgeries. As personalized medicine continues to evolve, the integration of biopsy results with other diagnostic modalities will enhance the ability to tailor treatments to individual patient profiles, driving growth in this segment of the market.

By Region

North America leads the personalized cancer medicine market, accounting for approximately 40% of the global market share. The primary drivers of this growth include the presence of advanced healthcare infrastructure, substantial investments in research and development, and a growing demand for innovative cancer therapies. The United States, in particular, has established itself as a hub for cancer research and personalized medicine, with numerous clinical trials and pharmaceutical companies focused on the development of targeted therapies and immunotherapies. The CAGR for the North American market is projected to be around 13% during the forecast period, reflecting the region's commitment to advancing personalized cancer treatment.

Europe is the second-largest market for personalized cancer medicine, holding a market share of about 30%. The growth in this region can be attributed to the increasing prevalence of cancer, rising healthcare expenditures, and ongoing research initiatives aimed at improving cancer care. Countries such as Germany, the United Kingdom, and France are at the forefront of personalized cancer medicine research and implementation. The European market is projected to grow at a CAGR of approximately 11% as healthcare providers and researchers collaborate to develop and implement personalized treatment strategies tailored to individual patient needs. Meanwhile, the Asia Pacific region is also emerging as a significant market, driven by rising cancer incidence rates and growing investments in healthcare infrastructure.

Opportunities

The personalized cancer medicine market is rife with opportunities for growth and innovation, particularly as advancements in genomics and biotechnology continue to emerge. One of the key opportunities lies in the expansion of biomarker testing and genomic profiling, which can provide critical insights into tumor characteristics and guide treatment decisions. As the scientific community discovers new biomarkers linked to various cancer types, companies that can develop and commercialize these tests will likely gain a competitive edge. Additionally, there is a growing demand for personalized therapies that leverage artificial intelligence and machine learning to analyze patient data and create individualized treatment plans. As healthcare organizations increasingly adopt these technologies, the market for personalized cancer medicine will continue to flourish.

Another promising opportunity exists in the realm of collaboration and partnership between pharmaceutical companies, research institutions, and healthcare providers. By working together, these stakeholders can accelerate the development and commercialization of innovative personalized cancer treatments. Collaborative efforts can also facilitate access to clinical trials, allowing patients to benefit from cutting-edge therapies. Furthermore, as healthcare systems worldwide shift towards value-based care models, the emphasis on personalized medicine is expected to grow, prompting investments in research and development aimed at identifying effective treatment protocols. This evolving landscape presents an exciting opportunity for market participants to explore innovative solutions that address the unique needs of cancer patients.

Threats

Despite the significant growth potential in the personalized cancer medicine market, several threats could impede progress. One of the foremost concerns is the rising costs associated with personalized therapies, which can pose challenges to patient access and affordability. Many personalized treatment options, particularly targeted therapies and immunotherapies, are expensive and may not be covered by all insurance plans. This disparity in access can lead to inequities in care, limiting the potential patient population for these innovative treatments. Additionally, regulatory hurdles surrounding the approval and reimbursement of personalized therapies can create delays in bringing new products to market, hindering overall growth.

Another major threat to the personalized cancer medicine market is the rapid pace of technological advancements. While innovation is essential for growth, it also leads to increased competition among companies vying to develop the latest therapies and diagnostic tools. As new players enter the market, established companies may face challenges in maintaining their competitive advantage. Additionally, the complexity of cancer biology and tumor heterogeneity means that not all patients will respond to personalized treatments, leading to questions regarding the overall efficacy and applicability of such approaches. Thus, stakeholders in this market must remain vigilant and adaptable to navigate these challenges effectively.

Competitor Outlook

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• AstraZeneca PLC
• Pfizer Inc.
• Amgen Inc.
• Genentech, Inc.
• Illumina, Inc.
• GSK (GlaxoSmithKline) plc
• AbbVie Inc.
• Celgene Corporation
• Johnson & Johnson
• Blueprint Medicines Corporation
• Myriad Genetics, Inc.

The competitive landscape of the personalized cancer medicine market is characterized by a diverse array of players, including pharmaceutical companies, biotech firms, and diagnostic laboratories. These participants are engaged in ongoing research and development efforts to innovate and expand their portfolios of personalized cancer therapies. Companies that can successfully navigate the complexities of regulatory approval and reimbursement processes while offering effective personalized treatments are likely to succeed in this dynamic market environment. Furthermore, strategic partnerships and collaborations are prevalent, enabling companies to leverage each other's strengths and expertise in advancing personalized medicine.

A significant force within this market is Roche Holding AG, a leader in the development of targeted therapies and diagnostics. Their portfolio includes several groundbreaking medications, particularly in the field of oncology, aimed at treating various cancer types through personalized approaches. Similarly, Merck & Co., Inc. is renowned for its immunotherapy products, including Keytruda, which has transformed the treatment landscape for several cancers. The company emphasizes the importance of companion diagnostics to ensure patients receive the most appropriate therapies based on their unique cancer profiles.

Another major player is Bristol-Myers Squibb Company, known for its contributions to immunotherapy and targeted treatments. Their commitment to research and partnerships with academic institutions has led to the development of innovative therapies that enhance personalized treatment options. Meanwhile, Novartis AG focuses on targeted therapies and has made significant strides in integrating genomic testing into their treatment protocols. These companies exemplify the competitive strategies shaping the personalized cancer medicine market, where innovation, collaboration, and patient-centric approaches are paramount.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Illumina, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca PLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genentech, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Celgene Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Myriad Genetics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 GSK (GlaxoSmithKline) plc
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Blueprint Medicines Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Personalized Cancer Medicine Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Specialty Clinics
    • 6.1.3 Cancer Research Institutes
    • 6.1.4 Ambulatory Surgical Centers
  • 6.2 Personalized Cancer Medicine Market, By Cancer Type
    • 6.2.1 Breast Cancer
    • 6.2.2 Lung Cancer
    • 6.2.3 Prostate Cancer
    • 6.2.4 Colorectal Cancer
    • 6.2.5 Leukemia
  • 6.3 Personalized Cancer Medicine Market, By Testing Type
    • 6.3.1 Genomic Testing
    • 6.3.2 Biomarker Testing
    • 6.3.3 Imaging
    • 6.3.4 Blood Tests
    • 6.3.5 Biopsy
  • 6.4 Personalized Cancer Medicine Market, By Therapy Type
    • 6.4.1 Targeted Therapy
    • 6.4.2 Immunotherapy
    • 6.4.3 Hormone Therapy
    • 6.4.4 Chemotherapy
    • 6.4.5 Radiation Therapy

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Personalized Cancer Medicine Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Personalized Cancer Medicine market is categorized based on

By Therapy Type

• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Chemotherapy
• Radiation Therapy

By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Leukemia

By End User

• Hospitals
• Specialty Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers

By Testing Type

• Genomic Testing
• Biomarker Testing
• Imaging
• Blood Tests
• Biopsy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• AstraZeneca PLC
• Pfizer Inc.
• Amgen Inc.
• Genentech, Inc.
• Illumina, Inc.
• GSK (GlaxoSmithKline) plc
• AbbVie Inc.
• Celgene Corporation
• Johnson & Johnson
• Blueprint Medicines Corporation
• Myriad Genetics, Inc.